Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2015 ASCO Annual Meeting /
New dexamethasone combination yields two-fold improvement in median PFS in multiple myeloma

29th May - 2nd Jun 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.06.15
Views: 4130
Rating:

Prof Meletios Dimopoulos - University of Athens, Athens, Greece

Prof Dimopoulos talks to ecancertv about the results from the phase III 'ENDEAVOR' study which looked at carfilzomib and dexamethasone (Kd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM).

ecancer's filming at ASCO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation